JP5492770B2 - ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 - Google Patents

ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 Download PDF

Info

Publication number
JP5492770B2
JP5492770B2 JP2010513710A JP2010513710A JP5492770B2 JP 5492770 B2 JP5492770 B2 JP 5492770B2 JP 2010513710 A JP2010513710 A JP 2010513710A JP 2010513710 A JP2010513710 A JP 2010513710A JP 5492770 B2 JP5492770 B2 JP 5492770B2
Authority
JP
Japan
Prior art keywords
phenyl
unsubstituted
benzimidazole
independently
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010513710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531313A5 (enExample
JP2010531313A (ja
Inventor
ホルヘ・アロンソ
アンドレーアス・リンデンシュミット
マルク・ナツァーレ
マティーアス・ウルマン
ニス・ハールラント
オマール・ルカイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2010531313A publication Critical patent/JP2010531313A/ja
Publication of JP2010531313A5 publication Critical patent/JP2010531313A5/ja
Application granted granted Critical
Publication of JP5492770B2 publication Critical patent/JP5492770B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010513710A 2007-06-26 2008-06-11 ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 Expired - Fee Related JP5492770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290800 2007-06-26
EP07290800.7 2007-06-26
PCT/EP2008/004639 WO2009000413A1 (en) 2007-06-26 2008-06-11 A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles

Publications (3)

Publication Number Publication Date
JP2010531313A JP2010531313A (ja) 2010-09-24
JP2010531313A5 JP2010531313A5 (enExample) 2011-07-07
JP5492770B2 true JP5492770B2 (ja) 2014-05-14

Family

ID=38646504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010513710A Expired - Fee Related JP5492770B2 (ja) 2007-06-26 2008-06-11 ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成

Country Status (12)

Country Link
US (1) US8735586B2 (enExample)
EP (1) EP2173721B1 (enExample)
JP (1) JP5492770B2 (enExample)
KR (1) KR20100023907A (enExample)
CN (1) CN101687815A (enExample)
AT (1) ATE539063T1 (enExample)
AU (1) AU2008267444A1 (enExample)
BR (1) BRPI0813271A2 (enExample)
CA (1) CA2691857A1 (enExample)
IL (1) IL202823A0 (enExample)
MX (1) MX2009013753A (enExample)
WO (1) WO2009000413A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
JP5774602B2 (ja) 2009-12-30 2015-09-09 アークル インコーポレイテッド 置換されたイミダゾピリジニル−アミノピリジン化合物
KR101477156B1 (ko) * 2010-08-25 2014-12-29 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
PE20140192A1 (es) 2010-10-06 2014-02-24 Glaxosmithkline Llc Derivados de bencimidazol como inhibidores de cinasa pi3
ES2571741T3 (es) 2011-03-31 2016-05-26 Bayer Ip Gmbh Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa
AU2012272937B2 (en) 2011-06-24 2016-09-29 Arqule, Inc Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
JPWO2013191188A1 (ja) * 2012-06-22 2016-05-26 住友化学株式会社 縮合複素環化合物
CN102924460B (zh) * 2012-11-05 2015-12-16 南京师范大学 一种4H-吡咯并[1,2-a]苯并咪唑衍生物及其合成方法和应用
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CN103130811B (zh) * 2013-03-11 2015-02-25 河南师范大学 一种5,6-二氢吡唑并[1,5-c]喹唑啉类化合物的合成方法
JP2016512219A (ja) 2013-03-15 2016-04-25 シンジェンタ パーティシペーションズ アーゲー 殺菌活性のあるイミダゾピリジン誘導体
WO2014151367A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as flap modulators
US9695149B2 (en) 2013-03-15 2017-07-04 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as flap modulators
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
CN105593224B (zh) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 作为溴结构域抑制剂的新型喹唑啉酮类化合物
MX2016006657A (es) 2013-11-22 2016-10-12 CL BioSciences LLC Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
CN103965136B (zh) * 2014-05-07 2016-09-07 苏州波菲特新材料科技有限公司 一种制备n-甲基噻唑啉-2-酮类化合物的方法
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
JP6964343B2 (ja) 2015-11-20 2021-11-10 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
CN106519250A (zh) * 2016-09-29 2017-03-22 辽宁石油化工大学 含氮小分子有机配体调节荧光发射性质的一维链状铜配位聚合物的制备方法
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
DK3562487T3 (da) 2016-12-29 2024-01-02 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloenzyminhibitorforbindelser
EP3615529B1 (en) 2017-04-26 2024-06-05 Basilea Pharmaceutica International AG, Allschwil Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
GB201800688D0 (en) 2018-01-16 2018-02-28 Redag Crop Prot Ltd Agricultural chemicals
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
AU2019295790B2 (en) 2018-06-29 2023-07-13 Forma Therapeutics, Inc. Inhibiting creb binding protein (CBP)
CN120365272A (zh) 2018-10-05 2025-07-25 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
CN110982806B (zh) * 2019-08-30 2022-09-02 浙江工业大学 一种蛋白质芳基衍生物及其制备方法
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN111206260B (zh) * 2020-02-12 2022-03-22 齐鲁工业大学 一种吡啶并[1,2-a]苯并咪唑类化合物的电化学合成方法
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020004679B1 (pt) * 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
BRPI0720131A2 (pt) * 2006-12-06 2014-02-04 Boehringer Ingelheim Int Glicocorticoides miméticos, métodos para fazê-los, composições farmacêuticas e usos dos mesmos.

Also Published As

Publication number Publication date
AU2008267444A1 (en) 2008-12-31
EP2173721A1 (en) 2010-04-14
KR20100023907A (ko) 2010-03-04
IL202823A0 (en) 2010-06-30
EP2173721B1 (en) 2011-12-28
CN101687815A (zh) 2010-03-31
JP2010531313A (ja) 2010-09-24
BRPI0813271A2 (pt) 2014-12-30
ATE539063T1 (de) 2012-01-15
US8735586B2 (en) 2014-05-27
CA2691857A1 (en) 2008-12-31
US20100261909A1 (en) 2010-10-14
WO2009000413A1 (en) 2008-12-31
MX2009013753A (es) 2010-01-26

Similar Documents

Publication Publication Date Title
JP5492770B2 (ja) ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成
JP5492769B2 (ja) 縮環されたベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的金属触媒合成
JP5271264B2 (ja) ベンゾイミダゾールおよびアザベンゾイミダゾールの位置選択的パラジウム触媒合成
AU2008282156B2 (en) Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2134682B1 (en) A transition metal catalyzed synthesis of n-aminoindoles
WO2010098496A1 (en) Process for producing tetrahydrotriazolopyridine derivative
HK1142894A (en) A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
HK1142895A (en) A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
HK1133880A (en) A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
HK1141287A (en) A transition metal catalyzed synthesis of n-aminoindoles
HK1141806B (en) Process for preparing 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine and derivatives thereof
JP2004331655A (ja) 含窒素複素環化合物の製造法および製造中間体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140303

R150 Certificate of patent or registration of utility model

Ref document number: 5492770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees